Prothena is a clinical-stage biotechnology company focused on diseases driven by protein misfolding and dysregulation. It develops antibody and other protein-targeting therapies for neurodegenerative conditions and rare peripheral amyloid diseases. Its pipeline draws on decades of expertise in pathogenic proteins such as those implicated in Alzheimer’s, Parkinson’s and related disorders.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 4.4 | — | -125.8 | — |
| Q3 2025 | 2.4 | — | -36.5 | — |
| Q4 2025 | 0 | — | -21.6 | — |
| Q1 2026 | 51.1 | — | 32.7 | — |
| Q2 2026 | 1 | -77.2% | -18.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Altimmune, Inc. (ALT), MapLight Therapeutics, Inc. (MPLT), Bank of Marin Bancorp (BMRC), TAT Technologies Ltd. (TATT), Gladstone Capital Corporation (GLAD), Monro, Inc. (MNRO)